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ABSTRACT 
KRISTEN N. KRUM: The role of apoptotic cells in the breakdown of B cell tolerance 
 (Under the direction of Barbara Vilen) 
We have recently shown that dendritic cells (DCs) and macrophages (Ms) are able 
to produce IL-6, sCD40L, and TNF that regulate autoreactive B cells. In systemic lupus 
erythematosus (SLE) autoreactive B cells are dysregulated allowing for their activation, 
autoantibody production, and loss of susceptibility to DC/M-mediated regulation. 
Apoptotic cells have been found to contribute to dysregulation and disease pathogenesis in 
SLE patients and lupus-prone mice, such as MerTKkd or lpr mice.  We hypothesized that if an 
apoptotic cell burden is responsible for dysregulation of autoreactive B cells, then removal 
of the apoptotic cell burden by injected C57BL/6 DCs and Ms should restore susceptibility 
of autoreactive B cells to DC/M-mediated regulation.  We found that autoreactive B cells 
from mice with clearance defects, MerTKkd and lpr, were not susceptible to DC/M-
mediated regulation.  Injecting C57BL/6 DCs and Ms into 2-12H/lpr mice restored 
autoreactive B cells to be susceptible to CD40L and increased basal pERK levels, while not 
reducing the apoptotic cell burden in the spleen.  Also, DC/M-treated 2-12H/lpr mice 
showed reduced autoantibody levels.  In DC/M treatedB6/lpr mice, susceptibility to IL-6 
was restored in autoreactive B cells, but there was no change in apoptotic cell burden in the 
spleen.  In addition, autoantibody production by B6/lpr mice was not affected by DC/M 
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treatment.  Further optimization of apoptotic cell removal and autoantibody production 
could make DC/M injection a potential therapeutic for SLE.  
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B cell tolerance 
During development of the B cell repertoire, there is expression of a vast array of B 
cell receptors (BCRs).  These BCRs can recognize foreign antigens of pathogens and as a by 
product there will also be the expression of receptors that recognize self antigens.  About 
50% of BCRs are specific for self-antigens [1].  Therefore, mechanisms are required to 
silence these autoreactive B cells.  Many mechanisms have been identified that regulate 
autoreactive B cells, including receptor editing, deletion, and anergy.  Without the ability to 
regulate autoreactive B cells, autoimmune diseases could occur, such as systemic lupus 
erythematosus, rheumatoid arthritis, or diabetes.   
Receptor editing and clonal deletion are the main mechanisms to regulate the B cell 
repertoire in the bone marrow [2].  Affinity of the BCR contributes to B cell fate [3-5].  
Stronger affinity to antigens drive B cells toward receptor editing or clonal deletion while 
lower affinity to antigens induces anergy [3, 4, 6].The initial response of self-reactive BCRs is 
receptor editing, which occurs through rearrangement of the variable, diversity and joining 
segments of the B cell receptor[2, 7].  The goal of receptor editing is to produce a new and 
less autoreactive BCR [2, 8].  Receptor editing continues until the receptor is either no 
longer autoreactive or when rearrangements are not possible [1].  Clonal deletion results 
when no more BCR rearrangements are possible or the BCR affinity to auto-antigen is too 
high [7, 8].  However, despite these mechanisms, some autoreactive B cells escape into the 
periphery where they are silenced through anergy, a process that impedes signaling 
through the B cell receptor [1, 6, 8].  Additionally, autoreactive B cells in the periphery can 
go through BCR editing and deletion [9-12]. 
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Innate and Cellular B cell Regulation 
The innate immune system allows for the rapid response to pathogens through the 
recognition of pathogen-associated molecular patterns (PAMPs) by pattern recognition 
receptors (PRRs) [13].  There are many PRRs, such as NOD-like receptors and RIG-I-like 
receptors, but of particular interest are toll-like receptors (TLRs) of which there are 13 
identified [14].  These receptors are displayed on macrophages, dendritic cells, B cells, T 
cells, natural killer cells, neutrophils, and many other cells including those within tissues [15, 
16].  TLRs are able to recognize viral and bacterial components, including both single- and 
double-stranded RNA and DNA, through TLR7 and TLR9 respectively [13-17].  Activation of 
NFB and IRF transcription factors occur when TLRs bind their respective ligand [13, 15, 16].  
These transcription factors promote the production of inflammatory cytokines and type I 
interferon, which induces an immune response and brings about clearance of the pathogen 
[13, 15, 16, 18].  There are also intracellular negative regulators of the TLR-signaling, such as 
TOLLIP and IRAK-M, which interact directly with molecules in the signaling pathway to 
inhibit pro-inflammatory cytokine production and the inflammatory response [13, 15, 16, 
18]. 
In addition to recognition of self-antigens by the BCR, B cells can detect self-antigens 
through TLRs.  Of particular interest are TLRs 7 and 9, which are expressed by B cells and 
recognize viral RNA and microbial DNA along with their ability to bind self-RNA and -DNA, 
respectively.  This ability to recognize self-antigens can promote autoimmune responses if 
they are not properly regulated.  Regulation of endosomal TLR-signaling in anergic 
autoreactive B cells is important in preventing the production of autoantibodies [19, 20].  
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When an autoreactive BCR binds self-antigen internalization occurs, however, through a 
JNK-mediated mechanism, the BCR-antigen endosome is unable to merge with a TLR7 or 
TLR9 containing endosome, ultimately blocking TLR stimulation [21].  On a lupus-prone 
MRL/lpr background, this TLR-signaling regulation is lost indicating that B cell tolerance 
during innate immune responses in part, relies on regulation within the endocytic pathway 
[21]. 
Autoreactive B cells can also be controlled through additional receptors.  One 
inhibitory receptor that regulates B cell-mediated immune responses is FcRIIb.  These 
responses are regulated through co-ligation of FcRIIb and BCR by IgG containing immune 
complexes.  This co-ligation inhibits BCR-signaling, activation, antigen presentation, 
proliferation, and antibody production [22-24].  It has been found that FcRIIb is a major 
regulator of autoreactive B cells, since mice lacking this receptor display a lupus-like 
phenotype including autoantibody production and glomerulonephritis [25, 26]. 
In addition to anergy, peripheral B cells specific for self antigens are regulated by 
regulatory B and T cells (Bregs and Tregs, respectively), plasmacytoid dendritic cells (pDCs), 
myeloid dendritic cells (DCs), and macrophages (Ms) [27-30].  B regulatory cells promote 
the formation of Tregs and tolerize autoreactive T cells [31].  The autoreactive T cells are 
therefore inactivated, which prevents their interaction with autoreactive B cells, thus 
blocking T-dependent autoantibody production [31].  In addition, both Bregs and Tregs 
produce IL-10, an anti-inflammatory cytokine, which inhibits T helper cell type 1 and T 
helper cell type 2 responses and the production of pro-inflammatory cytokines by dendritic 
cells and macrophages [27-30].  pDCs promote enhanced survival and autoantibody 
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production of autoreactive B cells in a TLR, soluble factor, and contact-dependent manner 
[32]. 
We have recently found that DCs and Ms repress autoreactive B cells in a TLR-
dependent mechanism [33, 34].  When DCs and Ms are LPS-stimulated, they produce 
soluble factors, IL-6, sCD40L, and TNF that repress TLR4-induced Ig secretion (Wagner, et 
al. in preparation) [33, 34].  Efficacy of DC/M-mediated regulation was obtained using 
mice deficient in IL-6, sCD40L, and TNF.  LPS-stimulated autoreactive B cells injected into 
mice lacking the three repressive factors were unable to be regulated, while those injected 
into wild type mice were regulated (Wagner et al. in preparation).  These results indicate a 
function of TLR4-induced repression in vivo by DCs and Ms.  Mechanistically, the soluble 
repressive factors prevented autoreactive B cells from differentiating into antibody 
secreting plasma cells (Wagner et al. in preparation)[33, 34].  Through this mechanism of 
repression, onset of autoimmunity is prevented by blocking the production of 
autoantibodies by autoreactive B cells. 
Repression of Ig secretion by these soluble factors is selective in that only B cells 
chronically stimulated by self-Ag repress Ig secretion while naive B cells secrete antibody 
[33, 34].  The selective DC/M-mediated regulation of autoreactive B cells suggests that 
chronic stimulation of the BCR is involved in the cells response to stimulation [35].  Chronic 
BCR stimulation promotes phosphorylation of ERK increasing basal levels and promoting an 
anergic phenotype [35].  When ERK phosphorylation in autoreactive B cells is blocked by 
MEK inhibitors, susceptibility to the repressive factors is lost (Lee et al. in preparation).  This 
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indicates that DC/M-mediated regulation of autoreactive B cells is dependent on 
MEK/ERK pathway. 
 
Systemic Lupus Erythematosus 
Systemic lupus erythematosus (SLE) is a chronic multisystemic autoimmune disease.  
It is characterized by the production of autoantibodies, which occurs when autoreactive B 
cells break tolerance and secrete autoantibodies specific for nuclear antigens, such as DNA, 
histones, snRNPs, and RNA.  These autoantibodies bind to apoptotic cells and create 
immune complexes, which are deposited in tissues throughout the body causing 
inflammation, tissue damage, and organ failure [36-39].  The organs affected by SLE are the 
kidneys, skin, blood vessels, joints, and the nervous system [40].  Additionally, 
autoantibodies to DNA and Smith (Sm) are used diagnostically since they associate with SLE 
clinical symptoms and disease activity [38, 41-48].  Anti-dsDNA antibodies are found in 
individuals with nephritis and tend to increase when a patient is about to have a flare in 
disease activity [37, 38, 45, 49].  Anti-Sm levels are prevalent in approximately 25-30% of 
SLE patients and lupus-prone mice and correlate with poor prognosis [50-52].  
Unfortunately, the etiology for SLE is unknown.  However, genetic and environmental 
components have been found to contribute to disease susceptibility. Many susceptibility 
loci have been identified in SLE patients that correlate with TLR and interferon (IFN) 
signaling pathways and apoptotic cell clearance that contribute to dysregulation and 
disease pathogenesis [53-55].  SLE patients present with a variety of symptoms and 
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exposure to different environmental factors and the presence of varied genetic components 
could contribute to this diversity. 
 
Murine models of SLE 
There are many murine models of SLE used to determine components of disease 
activity.  Two of the main models are the MRL/Mplpr/lpr (MRL/lpr) and the F1 generation, 
NZB/W, of the New Zealand Black (NZB) x New Zealand White (NZW).  Both of these models 
spontaneously develop SLE and produce autoantibodies and develop glomerulonephritis, 
lesions, and joint inflammation [56]  These mice are good models for SLE because their 
disease manifestations are similar to human SLE clinical symptoms. 
The lpr gene encodes for the Fas protein, which is involved in apoptosis.  In lpr (for 
lymphoproliferation) mice, there is a defect in the Fas protein, which makes the cells from 
these mice deficient in apoptosis.  This apoptosis defect allows autoreactive B cells that 
would have been deleted to escape into the periphery [56].  In addition, mice with the lpr 
gene have lympadenopathy, splenomegaly, and produce autoantibodies [56-58].  Recently, 
lpr mice have been shown to have an increase in apoptotic cells due to a phagocytosis 
defect in macrophages [59].  MRL/Mp mice have a genetic predisposition to develop 
autoimmune disease [57].  When MRL mice were being created, the lpr mutation arose 
spontaneously and was found to accelerate the time to disease onset in these MRL/lpr 
mice[57]. 
One antigen of specific interest in SLE is Smith (Sm).  SLE is the only autoimmune 
disease to have antibodies towards this antigen [50, 51].  About 25-30% of SLE patients 
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present with anti-Sm antibodies [44, 46, 52].  In addition, SLE patients who have anti-Sm 
antibodies tend to have a more severe disease and as a result have a poorer prognosis [44, 
46, 50, 51].  Ig-transgenic mice have been made that have the 2-12 heavy chain specific to 
Sm antigen [60].  Since they are only transgenic for the heavy chain, they are able to pair 
with endogenous light chains allowing for a variety of affinities to Sm.  These Ig Tg mice 
maintain anergy on non-autoreactive backgrounds [33, 34, 60].  When the 2-12H mice were 
crossed with lpr mice, making 2-12H/lpr mice, the autoreactive B cells break tolerance and 
secrete autoantibodies [59].  This same result was also seen when the 2-12H was placed on 
an MRL/lpr background [60]. 
 
Apoptotic cells 
Apoptosis, a form of programmed cell death, occurs continuously in organisms to 
allow for replacement of old and damaged cells.  During apoptosis, cells display nucleic 
antigens on their surface and release signals which promote their rapid clearance by 
multiple cell types including macrophages and dendritic cells [61, 62].  The ingestion of 
apoptotic cells promotes the production of anti-inflammatory cytokines, preventing a 
response to auto-antigens and inflammation [61, 63].  However, when rapid clearance does 
not occur, apoptotic cells can become necrotic or opsonized by auto-antibodies, leading to 
engulfment through receptors that promote pro-inflammatory cytokine production by 
phagocytes and inflammation [61, 63, 64].  
An inability to clear apoptotic cells allows for increased amounts of auto-antigen, 
since nuclear antigens are displayed on the surface of cells undergoing apoptosis [62].  
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Delayed clearance allows apoptotic cells to undergo secondary necrosis, which leads to 
blebbing of the membrane and release of potent auto-antigens into the extracellular space 
[62, 65-68].  This provides a source of nuclear antigen that can bind to TLRs and the BCR, 
leading to B cell activation and autoantibody production [69-71].  Production of 
autoantibody and the presence of auto-antigen via apoptotic cells allows for the formation 
of immune complexes (ICs).  Immune complexes are deposited in tissues throughout the 
body promoting an inflammatory response through binding to FcRs [36, 37, 39, 72-77]. 
Many murine models of lupus harbor defects in apoptotic cell clearance by 
macrophages.  In mice with Faslpr or MerTKkd deficiencies, macrophages are unable to 
phagocytose apoptotic cells [59, 78, 79]. In MerTKkd mice the defect was through the MerTK 
receptor and not FcR dependent, since there was no difference in clearance of opsonized 
apoptotic thymocytes between macrophages from MerTKkd mice and wild type mice [78, 
79].  Both Faslpr and MerTKkd mice have an increased apoptotic cell burden through TUNEL 
staining of the spleen and lymph nodes as compared to a wild type mouse [59, 78, 79].  
Increased apoptosis and clearance defects have been observed in SLE patients [36, 66, 67, 
75, 80-83].  One example is that cells in the bone marrow from SLE patients die more 
quickly than observed in cells from healthy controls by increased CD40 expression [84].  
Therefore, clearance defects have are common in lupus-prone mice and SLE patients and 
may contribute to disease pathogenesis. 
 Inflammation in autoimmunity is caused by self-antigens and their continual 
presence through a lack of clearance that promotes chronic inflammation.      Plasma cells 
have been found to migrate to inflamed kidneys in NZB/W F1 mice and increase the 
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antibody concentrations and immune complex deposition present in the kidney [85-87].  
Upregulation of chemokines, such as CXCL9, CXCL10, and CXCL11, by cells in the inflamed 
tissue promote migration of immune cells to the site and survival niches for infiltrating cells 
[86, 88].  IL-5, IL-6, TNF, BAFF, and CXCL12 production is required for plasma cell survival 
[85, 86, 88-90].  Plasma cell survival niches will be maintained through chronic inflammation 
driven by immune complex deposition and sustained presence of infiltrating immune cells 
[86, 87].  Furthermore, autoantibody-secreting plasma cells in the tissue enhance and 
perpetuate the pathogenesis occurring through formation and deposition of immune 
complexes within the tissue [86-88, 91].  The persistence of inflammation in the kidneys and 
other tissues in lupus patients will provide a permanent home for plasma cells producing 
both auto- and non-autoantibodies and leading to destructive damage of the organ [86-88]. 
 
Regulatory Defects in SLE 
A breakdown in any of the mechanisms regulating autoreactive cells can contribute 
to the development of autoimmune diseases/autoimmunity.  Defective regulation of TLR7, 
TLR9, and FcRIIb, contribute to autoimmunity through the production of autoantibodies 
[18, 25, 92-94].  Upregulation of TLR expression increases signaling and activation while 
promoting plasma cell differentiation to produce anti-RNA and anti-DNA autoantibodies 
[18, 20, 93].  Mice lacking TLR7 showed amelioration of disease symptoms [20, 93].  
Similarly, anti-RNA antibodies in human SLE is driven by TLR7 [20, 93].  Mice lacking TLR9 
have exacerbated disease symptoms [93].  Similarly in human SLE expression of TLR9 is 
increased on B cells and monocytes from patients with active disease and lupus nephritis 
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[95]. In many SLE patients, a loss of function defect has been found in FcRIIb and 
contributes to a loss in inhibitory signals and activation of many cell types promoting 
inappropriate or sustained signaling [24, 25, 96].  In addition, a defect in FcRIIb is present 
in a majority of murine autoimmune models, such as NZB and MRL, and when displayed in 
B6 mice, there is an increase in autoantibody production, indicating its role in immune 
regulation [26].   
Regulatory cells and cytokines are also dysregulated in SLE and contribute to disease 
pathogenesis.  Lupus-prone mice display an increase in IL-10 producing Breg cells.  Bregs 
reside in the marginal zone and are more than doubled in frequency in lupus-prone mice 
compared to wild type control mice [97].  The presence of Bregs in lupus patients show a 
similar trend where both the frequency and the absolute number of Bregs is increased [98].  
However, Bregs from SLE patients have been shown to produce to little or too much IL-10 
when compared to healthy controls, indicating that they can contribute to SLE disease [99, 
100].  Defects in apoptotic cell phagocytosis lead to an increased amount of apoptotic cells 
and impact cytokine production by dendritic cells and macrophages.  Macrophages from 
lupus-prone mice exhibit decreased pro-inflammatory cytokine production and an increase 
in IL-10 production compared to non-autoimmune prone mice [82, 97, 101].  Interestingly, 
macrophages cultured from lupus-prone mice without fetal bovine serum (FBS) showed 
cytokines produced at levels comparable to those from non-autoimmune mice [102].  The 
role of FBS in cytokine dysregulation of lupus-prone mice macrophages implicates the 
apoptotic cell burden in the mice, since FBS contains anionic lipids found on the apoptotic 
cell surface and delipidation of the FBS can fully remove the defect [102]. 
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The repressive factors produced by DCs and Ms through TLR4 stimulation are 
reduced in lupus-prone mice (Wagner et al. in preparation)[34, 103].  Stimulation through 
TLR4, TLR7, and TLR9 showed defects in IL-6 production by DCs from MRL, MRL/lpr, 
NZM2410, and NZB/W F1 lupus-prone mice along with reduced production of TNF by 
TLR4-stimulated MRL/lpr DCs (Wagner et al. in preparation) [103].  Similar defects in IL-6, 
sCD40L, and TNF production were seen in TLR4-stimulated Ms from MRL/lpr mice 
(Wagner et al. in preparation) [34].  However, DCs from B6/lpr mice secrete IL-6 at levels 
comparable to C57BL/6 DCs.  This indicates that the cytokine secretion defect is related to 
the MRL background and not to defects in Fas production [34, 103].  The inability of DCs and 
Ms from MRL/lpr mice to secrete the repressive factors suggests a point of dysregulation 
in autoreactive B cells.  Indeed, autoreactive B cells fail to repress Ig secretion in culture 
with DCs or Ms from MRL/lpr mice [34, 103].  This indicates that diminished secretion by 
lupus-prone DCs and Ms contribute to the break in tolerance.   
 
Natural and Pathogenic Autoantibodies 
Antibodies play an important role in immunity and autoimmunity by binding to 
foreign and self antigens and promoting removal of immune complexes.  Antibodies are 
produced in IgM, IgD, IgG, IgA, and IgE isotypes each having unique functions in pathogen 
neutralization and hypersensitivity.  Production of autoantibodies has been associated with 
a number of autoimmune diseases.  Of particular interest due to their protective and 
pathogenic roles are the IgM and IgG isotype autoantibodies. 
13 
 
Natural antibodies are produced by B cells that recognize both self and non-self 
antigens with a low affinity [104].  The majority of natural antibodies are IgM, but IgG and 
IgA have been found [105, 106].  Natural antibodies are beneficial in the clearance of 
pathogens and apoptotic cells [107, 108].  Natural antibodies promote clearance of 
apoptotic cells in a non-inflammatory manner through use of a C1q or mannose-binding 
lectin dependent pathway along with many other pathways that prevent the production of 
pro-inflammatory cytokines [107, 109, 110].  Prevention of activation and maturation of 
phagocytes is accomplished by natural antibody-mediated clearance [107].   
In lupus, autoantibodies contribute to inflammation, disease progression, and tissue 
damage.   IgG isotype antibodies are pathogenic in lupus patients and are produced by 
antigen-stimulated B cells [111, 112].  Through DNA sequencing, IgG autoantibodies had 
higher amounts of somatic mutations as compared to IgM antibodies, indicating affinity 
maturation of the BCR [113].  A portion of the dsDNA IgG antibodies bind to multiple 
antigens, especially glomerular proteins like -actinin and laminin involved in kidney 
structure [113-116].  Impact of IgG and IgM autoantibodies on lupus disease symptoms 
were determined through studies on their presence in affected tissues and disease activity 
in lupus patients, and mouse studies with NZB/W F1 and activation-induced deaminase 
(AID) deficient MRL/lpr.  SLE patients with higher IgM autoantibodies had a less severe 
disease as compared to patients with an increased amount of IgG autoantibodies [117-119].  
NZB/W F1 mice showed a change from IgM to IgG autoantibodies as their age increased 
[120].  Finally, MRL/lpr deficient in AID, required for class-switching and somatic 
hypermutation,  did not develop glomerulonephritis or cellular infiltration of the kidneys 
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and had an increase in anti-dsDNA IgM and survival as compared to MRL/lpr mice [121].  
IgM autoantibodies show a protective role in lupus by preventing nephritis or other lupus 
symptoms along with blocking anti-dsDNA IgG [116, 118-121]. 
 
Therapeutics 
There are many treatment options available for SLE patients, most of which focus on 
suppressing the immune system.  Some of the main treatments are NSAIDs, corticosteroids, 
antimalarials, azathioprine, cyclophosphamide, and methotrexate.  Although these 
treatments are effective, they possess side effects with prolonged use.  Corticosteroids, 
such as prednisone, inhibit cytokine secretion and are very common in treating SLE patients, 
since it is used for skin lesions, arthritis, and systemic disease including nephritis and 
vasculitis with the negative aspects being weight gain, diabetes, glaucoma, and increased 
risk of infection [40].  The benefits of antimalarials, hydroxychloroquine and quinacrine, is 
the sparing of steroids while providing synergistic effects through their combined usage and 
work by inhibiting antigen-processing and cytokine production[40, 122].  Side effects 
associated with antimalarials are skin discoloration and ophthalmologic damage [40].  
Cyclophosphamide is a chemotherapeutic agent and the main treatment for SLE patients 
with severe organ damage [40].  Nevertheless it can cause fertility problems and increased 
risk of infections [40].  Finally, azathioprine, which prevents nucleic-acid synthesis and 
spares the use of steroids, is used to treat nephritis and other SLE symptoms with toxic side 
effects in the bone marrow and gastrointestinal system [40]. 
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The toxicity of the conventional treatments has lead to recent advances in treating 
SLE.  Antibody to CD20 (Rituximab) removes B cells from the patient to prevent flares and 
improve clinical symptoms.  The chimeric antibody contains mouse components which can 
induce an immune response to the antibody [123, 124].  In addition, patients with 
incomplete B cell depletion show no improvement of symptoms [123-127].  Generation of a 
fully human anti-CD20 antibody will remove the concern for responses toward the mouse 
contributions to the current antibody.  Mixed results were seen in serum autoantibody 
titers, where those to RNA products were unaffected while those against dsDNA were 
reduced [123-126].  Since plasma cells do not express CD20, the inability of the Rituximab 
antibody to bind plasma cells and drive their depletion can explain these effects on serum 
autoantibody titers [128]. 
There are many ideas for transplantation of stem cells or bone marrow to alleviate 
disease or even cure lupus patients.  However, these studies in mice have resulted in mixed 
abilities to treat and prevent SLE pathogenesis [127].  In two studies looking at the ability of 
mesenchymal stem cells to treat disease symptoms in lupus-prone mouse models, one 
study found that NZB/W mice had worsened disease, while the study using MRL/lpr mice 
showed a decrease in nephritis symptoms [129, 130].  There are also studies determining 
whether hematopoietic stem cell transfer could be a method of treating lupus [127].  The 
use of mesenchymal stem cells along with bone marrow transplant showed an 
improvement in survival, renal condition, and a reduction in macrophages and double-
negative T cells in the spleen [131].  Glomerulonephritis improved in mixed chimera BXSB 
mice that were also treated with anti-CD40L and depleted of T cells [132].  Finally, a lupus 
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patient received a bone marrow transplant and was symptom free for 15 years post-
transplant [133].  All of these studies bring hope to this method of treatment as being a 
potential cure for lupus once efficacy is proved. 
A final method of treatment is the neutralization of cytokines.  Cytokines being 
targeted are IL-10, B cell activating factor (BAFF), TNF, CD40L, IL-6 and IFN[124, 125, 
134].  Implications of IL-10 produced at a higher rate in SLE patients are unknown, but 
contributes to plasma cell differentiation and increased apoptosis [82, 124].  Anti-IL-10 
given to NZB/W mice and SLE patients provided a protective effect in mice by preventing 
onset of autoimmunity while patients showed a quick response with clinical improvement 
[124].  BAFF is an important cytokine in B cell survival and plasma cell differentiation 
allowing autoreactive B cells to survive and become antibody-secreting cells that 
perpetuates disease [89, 124, 125].  In BAFF depleted mice, survival was enhanced and the 
disease was halted; however in patients, while reduction in B cells in the blood, anti-dsDNA 
antibodies and disease severity was not reduced [124, 134].  Lastly, TNF can have both a 
protective and detrimental effect on disease, since giving TNF to TNFlow-producing 
NZB/W mice slows disease pathogenesis, while its increased production in kidneys with 
glomerulonephritis correlates with disease severity [124].  When patients were treated with 
anti-TNF, there was an improvement in kidney proteinuria and only a temporary increase 
in autoantibodies [124, 125].  However, when undergoing this treatment, patients needed 
to be treated with an immunosuppressive agent to prevent a severe reaction.  While all of 
these cytokines reduced disease pathogenesis in open-label trials, more closed-label trials 
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are needed to confirm efficacy [135].  In addition, the previously mentioned treatments 
could potentially be used as a combination therapy to block multiple contributors.   
 
 
 
 
CHAPTER 2 
 
RESTORATION OF SUSCEPTIBILITY TO DC/M-MEDIATED REGULATION BY DC/M 
INJECTION 
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Introduction 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects 
multiple organ systems and is characterized by the production of anti-nuclear antibodies.  
These autoantibodies bind to apoptotic cells and debris to form immune complexes 
deposited throughout tissues that promote inflammation and tissue damage [36, 37, 39, 73, 
74, 81, 136-138].  Flares in disease activity correlate with increased titers of anti-dsDNA and 
inflammation [38, 41-46, 139, 140].  Many regulatory defects have been found in SLE, such 
as production and response to cytokines, complement, and apoptotic cells [61, 63, 71, 83, 
96, 99, 101, 102, 125, 141].  Ultimately, the etiology of SLE is unknown, but both genetic 
and environmental factors contribute to disease pathogenesis.  One factor that may 
contribute to SLE are apoptotic cells since they are found at increased levels in lupus 
patients and lupus-prone mice and contribute to immune complexes [36, 66, 67, 73, 75, 80-
82, 142, 143]. 
In healthy individuals, innate immune cells clear apoptotic cells quickly and promote 
an anti-inflammatory response through the production of IL-10 and TGF-([61, 64, 72, 144].  
This prevents the activation of autoreactive cells, maintains homeostasis, and promotes the 
formation of Bregs [144, 145].  SLE patients exhibit defects in clearing apoptotic cells [36, 
37, 66, 67, 73-75, 80-82, 84, 137, 142, 143, 146, 147].  The inability to clear apoptotic cells 
allows for secondary necrosis which is the loss of membrane integrity and subsequent 
leaking of nuclear components into the periphery [39, 62, 66, 137, 139, 147].   Presentation 
of auto-antigens stimulates autoreactive B cells through both a TLR- and BCR-dependent 
manner promoting autoantibody production [24, 92, 95, 148, 149].  The MerTKkd and lpr 
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mouse models have shown similarities to SLE patients through phagocytosis defects and 
increased apoptotic cell burden compared to wild type mice [59, 78, 79].  In addition, these 
mice also spontaneously produce autoantibodies indicating a dysregulation of autoreactive 
B cells [59, 78, 79]. 
Regulation of autoreactive B cells during innate immune responses is extremely 
important to prevent their activation.  One mechanism that we have identified is the 
production of IL-6, sCD40L, and TNF by TLR4 stimulated dendritic cells (DCs) and 
macrophages (Ms) (Wagner et al. in preparation) [33, 34].  We found that TLR4-stimulated 
B cells from 2-12H and 2-12H/V8 Ig transgenic (Tg) mice showed markedly diminished 
immunoglobulin (Ig) secretion when cultured with DCs, Ms, or recombinant IL-6, sCD40L, 
or TNF [33, 34].  We recently confirmed a role for the soluble repressive factors in B cell 
regulation in vivo and have found that IL-6 and sCD40L regulate TLR-induced Ig secretion by 
excluding phospho-ERK (pERK) from the nucleus (Wagner et al. and Lee et al. in 
preparation).  Defects in DC/M-mediated tolerance have been identified at both the level 
of IL-6, CD40L, and TNF production by lupus-prone DCs and Ms and in the ability of 
autoimmune prone B cells to respond to those factors and repress Ig secretion [33, 34, 103].  
Whether this is a consequence of ERK-mediated defects remains unclear. 
In this study, we show that coincident with an increased apoptotic cell burden 
autoreactive B cells from MerTKkd and lpr mice fail to repress Ig.  We also show that the 
diminished susceptibility to these repressive factors occurs coincident with decreased basal 
pERK.  This suggested that reducing the apoptotic cell burden may aid in restoring 
tolerance.  To test this, we injected DCs and Ms from C57BL/6 bone marrow.  We found 
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that autoreactive B cells from 2-12H/lpr mice injected with DCs and Ms regained 
susceptibility to sCD40L, but not to IL-6.  Surprisingly, we saw no change in the amount of 
apoptotic cells present by TUNEL analysis, or VAD-FMK staining.  In sero-positive 2-12H/lpr 
mice, DC/M treatment reduced serum autoantibodies.  However, in sero-negative mice 
they failed to prevent the onset of autoantibody production.  We found that autoreactive B 
cells from B6/lpr mice injected with DCs and Ms regained susceptibility to IL-6.  In B6/lpr 
mice, DC/M treatment showed no reduction in apoptotic cells by TUNEL staining.  In both 
sero-positive and sero-negative B6/lpr mice, DC/M treatment did not reduce or prevent 
serum autoantibody. These findings suggest that the injection of C57BL/6 DCs and Ms are 
able to induce tolerance to soluble repressive factors while not having an impact on the 
apoptotic cell burden, indicating that the apoptotic cell burden may not be the cause of the 
dysregulation of autoreactive B cells. 
 
Materials and Methods 
Mice. C57BL/6 (B6) and MRL/lpr non-transgenic mice were purchased from the Jackson 
Laboratory and bred in house (Bar Harbor, ME).  B6/lpr, 2-12H/B6 Tg, 2-12H/lpr Tg, and 2-
12H/V8 Tg mice have been described [56-59].  2-12H/V8 MerTKkd mice were created in 
house by breeding mice containing the MerTKkd gene from Glenn Matsushima with 2-12H 
and V8 mice and then crossing the two mice.  All animal experiments were approved by 
the Institutional Animal Care and Use Committee.   
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Reagents and Antibodies. LPS, TEPC 183, dsDNA, Phosphatase substrate, and 3-Amino-9-
ethyl-carazole from Sigma-Aldrich (St. Louis, MO), LPS was also purchased from Invivogen 
(San Diego, CA), mouse GM-CSF from PeproTech (Rocky Hill, NJ), Recombinant sCD40L 
(rsCD40L) was purchased from R&D Systems (Minneapolis, MN), Recombinant IL-6 was 
purchased from BD Pharmingen (San Jose, CA), SMA3000 (Sm) and histones were purchased 
from Immunovision (Springdale, AR).  33-60 and B7.6 (anti-IgM) were purified from 
hybridoma culture supernatants, M-CSF was produced by L Cells provided by Jeffrey 
Frelinger (University of Arizona), and IL-4 was produced by mIL-4 cells. Anti-CD19-PE, Anti-
CD3-FITC, Anti-CD11b-FITC, and Anti-CD11cPE antibodies purchased from BD PhosFlow (San 
Jose, CA), FITC-VAD-FMK purchased from Promega (Madison, WI), polyclonal Donkey anti-
mouse IgG from Abcam (Cambridge, MA), Strep-HRP from BD Pharmingen (San Jose, CA), 
and Strep-AP and goat anti-mouse Ig-AP was purchased from Southern Biotech 
(Birmingham, AL).  
 
Bone marrow-derived DC (BMDC) and M (BMM) Culture.  Bone marrow-derived DCs 
(BMDCs) (75% pure as CD11c+) were generated by culturing bone marrow cells with GM-CSF 
and IL-4 and bone marrow-derived Ms (BMMs) (95% pure) were generated by culturing 
with M-CSF in L cell media.  BMDCs were grown for 5 days and BMMs were grown for 8 
days.  
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Macrophage Condition Media (M CM).  Macrophages were sorted from C57BL/6 spleens 
using MoFlo (98% pure) and plated at 1x105/well in a 96-well plate with 30g/ml LPS for 4 
days.  Supernatants were harvested on day 4 and frozen for later use in B cell culture. 
  
B cell purification. Splenic B cells were isolated through negative selection by the StemSep B 
cell enrichment kit (StemCell Technologies, Vancouver, BC).  B cells were isolated from B6 
(95-99% pure), B6/lpr (88-99% pure), 2-12H/B6 (94-98% pure), 2-12H/lpr (76-98% pure), 2-
12H/lpr DC/M injected (65-90% pure), and B6/lpr DC/M injected (95-99% pure).  FICOLL 
gradient enrichment along with T cell depletion using biotinylated anti-CD3 was used to increase 
purity of B cells from B6/lpr and 2-12H/lpr mice.  
 
B cell culture.  Purified B cells (1x105 per well in a 96-well plate) were cultured with 30 μg/ml 
(Sigma) or 15g/ml (Invivogen) LPS alone or with rIL-6, rsCD40L, or M CM for 3 (ELISpot) 
or 4 (ELISA) days.   
 
ELISAs.  Total IgM was captured with anti-IgM (33-60) and detected with biotinylated anti-
IgM
 
(B7.6) antibody and Streptavidin-AP as previously described [24]. Anti-nucleosome 
antibodies were captured with histones and dsDNA, and the detected with either polyclonal 
anti-IgG-AP (Abcam), polyclonal anti-Ig-AP (Southern Biotech) or biotinylated anti-IgM 
(B7.6) antibodies and Streptavidin-AP. Anti-dsDNA antibodies were captured with dsDNA 
and detected with either polyclonal anti-IgG-AP (Abcam) or biotinylated anti-IgM (B7.6) 
antibodies and Streptavidin-AP. Purified mouse IgMa/ (TEPC 183) served as the standard 
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control for Total IgM, anti-nucleosome IgM, anti-dsDNA IgM, and anti-nucleosome (PL2-6) 
antibodies served as the standard control for anti-nucleosome IgG, Ig, and anti-DNA (PA4) 
antibody served as the standard control for anti-dsDNA IgG antibody.  
 
ELISpot.  ELISpots were performed using plates (Millipore, Billerica, MA) coated with 10U/ml 
Sm (Immunovision, Springdale, AR).  B cells were harvested 3 days after culture with LPS, IL-
6 and sCD40L.  Cells were plated at 8x104 cells per well and diluted 1:2 into 3-5 additional 
wells. After 8 hour incubation on Sm-coated plates, cells were washed off the plates and 
secreted antibody remaining on the plates was detected using biotin-labeled anti-IgM 
antibody (B7.6), followed by Streptavidin-HRP (BD Biosciences). Spots were developed using 
the substrate 3-amino-9-ethylcarbazole (Sigma-Aldrich). Plates were scanned and analyzed 
using the Immunospot ELISpot analyzer (Cellular Technology Ltd., Cleveland, OH).  
 
BMDC/BMM injection.  2-12H/lpr and B6/lpr mice were injected i.v. every 5 days with 
6x106 BMDCs and 2x106 BMMs in 200l of PBS or 200l only (controls) for 6-11 weeks.  
Mice were bled every 1-2 weeks to determine serum autoantibody production. 
 
TUNEL.  Spleen tissues were fixed in 10% formalin, embedded in paraffin, and sectioned.  
Deoxynucleotidyl-transferase-mediated UTP nick-end labeling (TUNEL) assays were 
performed using In Situ Cell Death Detection Kit, Fluorescein (Roche, Germany) according to 
manufacturer’s instructions.  Hoechst staining was used for counterstaining to visualize 
nuclei.  Images were obtained with Zeiss710 with a 10x objective.  Image processing and 
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analysis was done using ImageJ.  Quantification of apoptotic cells in each mouse spleen was 
determined through counting apoptotic cells from 5-10 images and averaging the number 
of apoptotic cells from all images counted. 
 
Statistical Analysis.  Data was analyzed using the Mann-Whitney Rank Sum test. Significant 
p values  < 0.05 are denoted by *, p values  < 0.01 are denoted by **, p values < 0.001 are 
denoted by ***. 
 
Results 
Dysregulation of DC/M-mediated tolerance of autoreactive B cells from MerTKkd and lpr 
mice  
During innate immune responses, autoreactive B cells are repressed by IL-6, sCD40L 
and TNF secreted by TLR4-activated DCs and Ms [33, 34, 103].  In lupus-prone mice, the 
susceptibility of autoreactive B cells to the repressive factors is lost allowing autoantibody 
secretion.  We reasoned that perhaps the increased burden of apoptotic cells and the 
exposure of nuclear self-antigens on dying cells might disrupt the mechanisms that regulate 
autoreactive B cells during innate immune responses. To address this, we co-cultured LPS-
stimulated B cells from 2-12H/V8 MerTKkd and 2-12H/V8 mice with ex vivo DCs and Ms 
sorted from C57BL/6 mice.  At B cell:DC ratios of 10:1 and 20:1, we found that Ig secretion 
from 2-12H/V8 was repressed in a dose dependent fashion as previously reported [33, 34].  
However, Ig secretion from those B cells exposed to an increased burden of apoptotic 
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debris (2-12H/V8 MerTKkd) was significantly less repressed than 2-12H/V8 B cells (Figure 
2.1A).   
To confirm that the secreted products of DCs and Ms conferred the loss of 
susceptibility to the repressive factors, we cultured LPS-stimulated B cells from 2-12H/V8 
and 2-12H/V8 MerTKkd mice with MCM. This CM was prepared from sorted ex vivo 
C57BL/6 Ms cultured for 4 days with LPS.  It was previously shown to contain IL-6, sCD40L, 
and TNF and to repress TLR4-induced Ig secretion [33, 34].  While Ig secretion from LPS-
stimulated B cells from 2-12H/V8 mice was repressed 26-82%, Ig secretion from 2-
12H/V8 MerTKkd mice was only repressed 0-53% (Figure 2.1B).  Similarly, recombinant IL-6 
and sCD40L were unable to repress B cells from the 2-12H/V8 MerTKkd mice.  This suggests 
that during innate immune responses, B cells from mice harboring an increased burden of 
apoptotic cells are less susceptible to regulation by the secreted products of DCs and Ms. 
Although the MerTKkd mice are known to have a defect in clearing apoptotic debris, 
it is possible that other secondary affects were impacting the B cell response to innate 
stimuli.  To address this, we assessed whether B cells from Fas-deficient mice could be 
repressed.  Fas-deficient mice are known to harbor an increased burden of apoptotic debris 
[59].  To determine whether B cells from these mice exhibited similar defects, we LPS-
stimulated B cells from 2-12H/B6 and 2-12H/lpr mice with M CM and recombinant 
cytokines.  As shown in Figure 1C, anti-Sm antibody secreting cell (ASC) formation from 2-
12H/B6 B cells was repressed 56-65%, however, B cells from 2-12H/lpr mice were only 
repressed 3-43% by M CM or recombinant cytokines.   
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Apoptotic cells increased and pERK levels decreased in MerTKkd and lpr mice 
We predicted that if apoptotic cells were responsible for the diminished 
susceptibility to DC/M-mediated tolerance, these cells would be evident by TUNEL.  
Comparison of spleens from 2-12H/V8 and 2-12H/V8 MerTKkd mice confirmed our 
prediction by the increased TUNEL-positive cells present in mice with the MerTKkd gene 
(Figure 2.2A and B).  We saw trends of increased apoptotic cell levels in Fas-deficient mice 
that showed similar defects in B cell susceptibility (Figure 2.2C and D).  Lupus-prone MRL/lpr 
mice were also examined and found to display a trend in increased burden of apoptotic cells 
(Figure 2.2C and D).  These results indicate a role for apoptotic cells to dysregulate DC/M-
mediated tolerance of autoreactive B cells.  
The ability of IL-6 and sCD40L to repress Ig secretion is in part dependent on 
activation of ERK 1 and 2.  Blockade of ERK phosphorylation by MEK inhibitors in 
autoreactive B cells prevents their susceptibility to DC/M-mediated tolerance, indicating a 
role for pERK 1 and 2 in reprogramming of the response by IL-6R and CD40 (Lee et al. in 
preparation).  To determine whether ERK phosphorylation was dysregulated in the B cells 
that lacked susceptibility to IL-6, sCD40L and MCM, we measured the basal levels of pERK 
in B cells from 2-12H/V8 MerTKkd and 2-12H/lpr mice.   B cells from both mice that 
harbored decreased susceptibility and increased apoptotic cells had reduced basal pERK 
levels as compared to their anergic B cell controls (Figure 2.3 A and B).  Their levels of pERK 
were comparable to naïve B cells from C57BL/6 mice, which are not susceptible to 
regulation by the repressive factors.  Our findings indicate that an over abundance of 
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apoptotic cells contributes to dysregulation of autoreactive B cell susceptibility to DC/M-
mediated tolerance likely through a pERK dependent mechanism.    
 
Injection of DC/M restores susceptibility of autoreactive B cells to CD40L 
Loss of susceptibility to IL-6, sCD40L, and TNF in autoreactive B cells is correlated 
with an increased presence of apoptotic cells.  We hypothesized that removal of apoptotic 
cell burden from lpr mice would restore susceptibility of autoreactive B cells to the soluble 
repressive factors.  To test this, we injected 2-12H/lpr mice with C57BL/6 DCs and Ms 
every five days for six weeks and then assessed whether B cells from these mice regained 
susceptibility to rIL-6, rsCD40L, and MCM.  As shown in Figure 2.4A, autoreactive B cells 
from 2-12H/lpr mice treated with DCs and Ms were repressed in response to rsCD40L and 
MCM, but not in response to IL-6 as compared to the PBS injected and 2-12H/B6 controls 
(Figure 2.4A).  After 8 weeks of DC/M treatment, basal pERK levels of B cells were found 
to be increased to levels comparable to those seen in B cells from 2-12H/B6 mice (Figure 
2.4E).  This indicates that injection of C57BL/6 DCs and Ms can induce susceptibility of 
previously unsusceptible autoreactive B cells to DC/M-mediated regulation and restore 
pERK to levels associated with anergy. 
We hypothesized that the increased amount of apoptotic cells was the trigger for 
dysregulation of autoreactive B cells from MerTKkd and lpr mice.  To assess whether 
injecting DCs and Ms into 2-12H/lpr mice reduced apoptotic cell burden, we performed 
TUNEL analysis on spleen sections.  Apoptotic cells are identified through broken DNA by 
TUNEL staining or by any activated caspases with VAD-FMK staining.  TUNEL analysis 
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revealed no reduction in apoptotic cells in the spleens of DC/M treated 2-12H/lpr 
compared to PBS treated 2-12H/lpr mice (Figure 2.4 B and D).  Apoptotic cell analysis by 
VAD-FMK staining of splenocytes indicated no reduction of apoptotic cells in the DC/M 
compared to PBS treated 2-12H/lpr mice (Figure 2.4C).  Therefore, the induced 
susceptibility of autoreactive B cells from DC/M-treated 2-12H/lpr mice appear to not be 
due to the apoptotic cell burden. 
 
Anti-Sm antibodies reduced in DC/M-treated sero-positive 2-12H/lpr mice 
We and others have shown that B cells from mice with MerTKkd or lpr genes are 
dysregulated allowing for the production of autoantibodies [59, 78, 79].  Autoantibodies in 
SLE patients and lupus-prone mice are able to exacerbate symptoms and correlate with 
flares in disease activity [38, 41-46, 48, 139, 140].  Certain treatments for SLE have been 
shown to reduce autoantibody production along with disease symptoms [133, 150-162].  
Therefore, one of our goals was to test whether the injection of DCs and Ms would be 
able to reduce autoantibody levels or prevent them from being produced, particularly of the 
pathogenic IgG class [121].  Anti-Sm antibodies are produced by 2-12H mice and in SLE 
patients correlates with a more severe disease and worse prognosis [41-46, 140].  When 
testing DC/M injection in 2-12H/lpr mice, we found that sero-positive mice treated with 
DCs and Ms had reduced anti-Sm antibodies and when a couple of mice stopped receiving 
injections, they continued to remain sero-negative or making very low levels (Figure 2.5A).  
On the other hand, sero-negative mice were induced to make anti-Sm antibodies after the 
first injection, which were maintained at a constant concentration throughout the entire 
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experimental period (Figure 2.5B).  Unfortunately, in both of these experiments the controls 
were not sufficient to make a clear conclusion, since only one PBS-treated 2-12H/lpr mouse 
made antibodies in each cohort.  In addition, the PBS-treated mouse in the sero-negative 
cohort never produced antibody at the levels seen in mice in the sero-positive cohort.  
Therefore, our results indicate a potential role for DCs and Ms to regulate IgM 
autoantibody production in Tg lpr mice.   
 
Defect in DC/M-mediated susceptibility of autoreactive B cells from B6/lpr mice 
We previously used 2-12H/lpr mice that produced B cells specific for Sm.  In order to 
determine the impact on a B cell repertoire that was more comparable to SLE patients, we utilized 
B6/lpr mice.  These non-Tg mice were similar to the 2-12H/lpr in their spontaneous production of 
autoantibody and increased apoptotic cell burden.  However, they had a B cell repertoire that 
contained autoreactive and non-autoreactive B cells.  To determine whether the autoreactive B cells 
from B6/lpr mice were not susceptible to DC/M-mediated tolerance, we isolated B cells from 
C57BL/6 and B6/lpr mice.  We found that autoreactive B cells from B6/lpr mice were not susceptible 
to DC/M-mediated regulation while those from C57BL/6 mice were regulated (Figure 2.6B).  In 
addition, Total IgM production was unaffected by rIL6 and rsCD40L in B cells from both C57BL/6 and 
B6/lpr mice (Figure 2.6A).  This indicates that the loss of susceptibility to the soluble repressive 
factors is maintained in non-Tg mice.   
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DC/M-mediated susceptibility restored in autoreactive B cells from DC/M injected B6/lpr 
mice 
B6/lpr mice were utilized to determine the impacts this DC/M treatment would 
have on a non-Tg mouse with increased apoptotic cells.  Since these mice had both 
autoreactive and non-autoreactive B cells, there could be a difference in the outcomes 
identified from the previously treated 2-12H/lpr mice.  B6/lpr mice were injected with DCs 
and Ms as described above for 10 weeks.  When tested for susceptibility to IL-6 and 
CD40L, autoreactive B cells from DC/M treated B6/lpr mice displayed susceptibility when 
cultured with rIL-6, however not when cultured with rsCD40L (Figure 2.7B).  Total IgM 
production by B cells was unaffected in all mice (Figure 2.7A). Our results suggest that 
autoreactive B cells from B6/lpr mice treated with DCs and Ms have restored susceptibility 
to IL-6.  This indicates that DC/M treatment can restore DC/M-mediated regulation in 
autoreactive B cells from non-Tg mice. 
We utilized sero-positive and sero-negative B6/lpr mice.  Apoptotic cell burden was 
determined by TUNEL-staining of spleen sections from DC/M treated B6/lpr mice 
compared to C57BL/6 and PBS-treated B6/lpr mice.  Both sero-negative and sero-positive 
DC/M-treated B6/lpr mice showed similar trends to the DC/M 2-12H/lpr mice where 
apoptotic cells were not reduced as compared to PBS injected and C57BL/6 mice controls 
(Figure 2.7C).  These results indicate that clearance of apoptotic cells by injected DCs and 
Ms are not improved in non-Tg mice.   
Since the 2-12H/lpr mice are only capable of making anti-Sm IgM, we tested B6/lpr 
mice that could make all isotypes of Ig and antibodies specific for additional nuclear 
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antigens.  Antibodies against dsDNA and nucleosomes are of particular interest due to their 
correlation with disease flares and lupus nephritis and as the initial antibodies produced in 
SLE patients due to the release of nucleosomes from uncleared apoptotic cells, respectively 
[38, 39, 62, 66, 111, 136, 143].  We used sero-positive and sero-negative mice to determine 
whether autoantibody production could be terminated or prevented.  Anti-dsDNA and anti-
nucleosome antibodies were quantified by ELISA for both IgM and IgG isotypes.  
Autoantibody production in sero-positive B6/lpr mice treated with DCs and Ms were 
unaffected except for one mouse that showed an increased production in both anti-dsDNA 
and anti-nucleosome IgM (Figure 2.8A).  In sero-negative mice, autoantibody production 
was not prevented or halted in DC/M treated B6/lpr mice compared to PBS injected 
B6/lpr mice (Figure 2.8B).  These results indicate that the injection of DCs and Ms are 
unable to affect the autoantibody production in either sero-positive or sero-negative B6/lpr 
mice. 
 
Discussion 
During an innate immune response, autoreactive B cells are regulated by soluble 
repressive factors (Wagner et al. in preparation)[33, 34].  However, we show that 
autoreactive B cells from mice harboring an increased burden of apoptotic cells are not 
susceptible to the repressive factors and thus secrete Ig in response to TLR4 stimulation.  
There is a correlation between the inability to repress Ig secretion of autoreactive B cells 
with an increased burden of apoptotic cells.  In addition, the elevated basal pERK levels 
associated with B cell anergy is lost coincident with loss of susceptibility to the repressive 
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factors.  Treatment of these mice with C57BL/6 DCs and Ms restored susceptibility to the 
soluble repressive factors and increased basal pERK levels to levels comparable to those 
seen in anergic B cells.  However, the apoptotic cell burden was unaffected in the DC/M 
treated mice.  The autoantibody production in DC/M treated mice was reduced in sero-
positive Tg mice, but unaffected in sero-negative Tg and all non-Tg mice. 
Mice that displayed an increased burden of apoptotic cells had autoreactive B cells 
that were not repressed by IL-6, sCD40L, or TNF.  We induced tolerance to IL-6, sCD40L, 
and TNF in autoreactive B cells of DC/M injected lpr mice, even though the apoptotic cell 
burden was not reduced.  These results indicate that our hypothesis that susceptibility to 
the repressive factors would be restored through the removal of the apoptotic cell burden 
was not supported due to an inability to reduce the apoptotic cell burden although DC/M-
mediated susceptibility was restored in autoreactive B cells from DC/M-treated mice.  
There are several reasons that could explain why the apoptotic cell burden was not 
reduced.  First, the injected DCs and Ms may not have homed to the spleen.  Ms enter 
many different tissues, while DCs home mainly to lymph nodes [63, 163].  Since the cells are 
being injected through the tail vein, many of them will be cleared in the liver and some may 
be impeded in the lungs and prevent them from reaching the spleen.  Although there is not 
a net reduction of apoptotic cells seen in the spleen, there could be clearance occurring 
system wide. 
Immune complexes in lupus patients and lupus-prone mice are formed from 
autoantibody binding to apoptotic debris.  MRL/lpr mice that were unable to make IgG 
antibodies no longer displayed kidney inflammation, cellular infiltration, and nephritis [121].  
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In addition, the IgM autoantibodies produced in these mice appeared to be similar to 
natural antibodies through a lack of somatic mutation [121].  Therefore, the pathogenic 
forms of autoantibodies in SLE patients and lupus-prone mice are those of the IgG isotype.  
There was an increase in the IgM autoantibody levels of the Tg mice that were sero-
negative at the start of the injections, which could be to promote clearance of apoptotic 
cells.  However, sero-positive 2-12H/lpr mice receiving DCs and Ms exhibited decreased 
autoantibody levels.  This could indicate that enough clearance of apoptotic cells occurred 
to reduce IgM production.  Alternatively, it might reflect a role for DCs and Ms on 
plasmablast formation and survival, although the exact mechanism is unknown.  
Unfortunately, the majority of B6/lpr mice injected with cells showed no change in the 
autoantibody levels.  One caveat is that IgG autoantibodies tend to be produced by long-
lived plasma cells, have a 6-8 day half-life in mice and 7-21 day half-life in humans, and are 
difficult to deplete [164, 165].  Thus the sero-positive mice may not be able to become sero-
negative.  We also saw that autoantibody production was not delayed in DC/M treated 
sero-negative mice, indicating that this treatment is unable to prevent plasma cell 
formation.   
We utilized the spleen to determine apoptotic cell burden, since it has previously 
been shown to harbor the burden and because we obtained the B cells from here for the 
susceptibility experiments.  There seems to be enough cells making it to the spleen to 
induce susceptibility, but not enough to be clearing the apoptotic cells or having an impact 
on the autoantibody levels.  Therefore, additional studies should be conducted to 
determine the localization of the injected cells, which will allow for identification of areas 
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with the highest concentration of injected cells to observe for changes in apoptotic cell 
burden.  By identifying the localization of the cells injected through the tail vein, we will be 
able to determine to what organs they localize, such as the kidneys or spleen.   Additionally, 
cells could be directly injected into the spleen to see if they have an impact on clearance of 
apoptotic cells.  This would remove the requirement of cells having to home to the spleen 
after injection through the tail vein.  These studies would allow for the development of 
improved approaches to the DC/M treatment. 
The length of survival of the injected cells is unknown, which could explain why 
there is no difference in the amount of apoptotic cells in the dendritic cell and macrophage 
injected mice.  One reason is because the injected cells could be dying at about the same 
rate as the apoptotic cells are being cleared by the live injected cells.    Also, knowing the 
length of survival of the injected cells will be beneficial to determine how many are dying, at 
what rate, and if there is anything that could be done to improve their survival and 
ultimately their impacts on the system.  The use of the previously mentioned labeling of 
injected cells would also allow for the determination of survival.  This would be an area 
where the use of bone marrow chimeras would be beneficial, since the healthy dendritic 
cells and macrophages would be continually produced and the rate of new live cells injected 
would be irrelevant.  DC/M injection may be a good therapeutic for lupus if optimization 
improves the removal of the apoptotic cell burden and reduction of serum autoantibody 
levels. 
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Figure 2.1. B cells from mice harboring clearance defects are not susceptible to DC/M-
mediated regulation. B cells (1x105) from 2-12H/V8 and 2-12H/V8 MerTKkd mice were 
stimulated with LPS (30 g/mL) and cultured in the presence or absence of DCs or Ms 
from C57BL/6 mice at ratios of 10:1 or 20:1 B cell:DC/M (A) or MCM, rIL-6 (20 ng/mL) or 
rsCD40L (100 ng/mL) (B) for 4 days.  IgMa/k was quantified by ELISA.  (C) B cells (1x105) from 
2-12H and 2-12H/lpr were stimulated with LPS (30 g/mL) and cultured in the presence or 
absence of MCM, rIL-6 (20 ng/mL) or rsCD40L (100 ng/mL) for 3 days when B cells were 
harvested and plated on an Sm-specific enzyme-linked immunosorbent spot (ELISpot) plate 
for 8 hours. Data represent at least 3 experiments.  (*P < 0.05, **P < 0.01, ***P < 0.001) 
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Figure 2.2.  Lupus-prone mice harbor an increased burden of apoptotic cells.  Apoptotic 
cells in spleens were detected by TUNEL (green) for 2-12H/V8 and 2-12H/V8 MerTKkd (A) 
and for C57BL/6, B6/lpr, and MRL/lpr (C).  B and D are the quantification of apoptotic cells 
in images. Images representative of at least 2 experiments with an n of 3. (*P < 0.05) 
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Figure 2.3. Reduced pERK levels in B cells from MerTKkd and lpr mice.  B cells (3x106) 
isolated from C57BL/6, 2-12H/V8, and 2-12H/V8 MerTKkd (A) and C57BL/6, 2-12H/B6, and 
2-12H/lpr (B) were lysed without stimulation and immunoblotted for pERK and total ERK.  
Normalized pERK to Total ERK then compared mouse strains.  Representative of at least 3 
experiments. 
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Figure 2.4. Injecting DC/M into 2-12H/lpr mice restores susceptibility to CD40L. 2-
12H/lpr mice were injected with PBS (200 L) or DCs (6x106) and Ms (2x106) every 5 days 
for 6 weeks.  (A) At six weeks, B cells (1x105) were isolated and stimulated with LPS (30 
g/mL) in the presence or absence of rIL-6 (20 ng/mL), rsCD40L (100 ng/mL), or MCM for 
3 days and were then harvested and plated on Sm-specific ELISpot plates for 8 hours to 
determine the number of antibody secreting cells (ASCs).  Spleen sections from PBS and 
DC/M treated 2-12H/lpr and control mice were stained with TUNEL (D) and quantified (B).  
(C) VAD-FMK staining of splenocytes (5x105) was utilized as another measure of apoptotic 
cells. (E) B cells (1x105) were isolated and lysed without stimulation and immunoblotted for 
pERK and Total ERK.  Data represent at least 2 experiments with an n of 3. (*P < 0.05, **P < 
0.01) 
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Figure 2.5 Serum autoantibody levels are reduced in 2-12H/lpr DC/M injected mice. 
Sero-positive (A) or sero-negative (B) 2-12H/lpr mice were injected with PBS (200 L) or DCs 
(6x106) and Ms (2x106) every 5 days for 20 weeks and bled every 1-2 weeks.  Serum 
autoantibody levels were quantified by Sm ELISA.  Data represent at least 3 mice except for 
PBS treated mice in A and B where n = 1. 
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Figure 2.6 Autoreactive B cells from B6/lpr mice are not susceptible to Ig repression by   
IL-6 and sCD40L. B cells (1x105) from non-age matched C57BL/6 (6-7weeks) and B6/lpr (12-
16 weeks)mice were stimulated with LPS (15 g/mL) and cultured in the presence or 
absence of rIL-6 (5 ng/mL) or rsCD40L (25 ng/mL) for 4 days. Total IgM and anti-nucleosome 
Ig was quantified by ELISA.  Data represents an n=3. (*p < 0.05) 
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Figure 2.7. Susceptibility regained to rIL-6 and apoptotic cell burden of DC/M injected 
B6/lpr mice are unchanged. Sero-negative B6/lpr mice were injected with DCs (6x106) and 
Ms  (2x106) or PBS (200 L)every 5 days for 10 weeks.  At 10 weeks, B cells (1x105) were 
isolated and stimulated with LPS (15 g/mL) in the presence or absence of rIL-6 (5 ng/mL) or 
rsCD40L (25 ng/mL) and cultured for 4 days.  Total IgM (A) and anti-nucleosome Ig (B) were 
quantified by ELISA.  (B) Spleen sections from PBS and DC/M treated sero+ and sero- 
B6/lpr and control mice were stained with TUNEL and quantified. Data represents at least 
an n=3. (*p < 0.05) 
 
 
 
 
 
43 
 
 
 
Figure 2.8.  Serum autoantibody levels are unchanged in B6/lpr DC/M injected mice. 
B6/lpr sero-positive (A) and sero-negative (B) mice were injected with PBS (200ml) or DCs 
(6x106) and Ms (2x106) every 5 days for 7 weeks and bled every 1-2 weeks.  Serum anti-
nucleosome IgM and IgG and anti-dsDNA IgM and IgG were quantified by ELISA.  Data 
represent at least 3 mice except for the DC/M injected in sero-positive which represents 2 
mice. 
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SLE is a chronic multisystemic autoimmune disease characterized by the production 
of autoantibodies.  The autoantibodies recognize nuclear components that are presented 
on the surface of apoptotic cells and debris allowing for formation of immune complexes.  
In SLE patients, the phagocytes do not function correctly, allowing for a build-up of 
apoptotic cells [36, 66, 67, 72, 75, 80, 81, 83, 96, 100, 136, 143].  This increases the 
presence of self-antigen in SLE patients that contributes to the dysregulation of 
autoreactive B cells and promotes their production of autoantibodies [14, 61, 62, 66, 70, 95, 
136, 137]. Once formed, the immune complexes are deposited in tissues throughout the 
body causing inflammation and ultimately tissue damage [38, 91].  Some of the tissues the 
immune complexes are deposited in are the skin, kidneys, blood vessels, joints, and the 
nervous system [37-39, 74, 75, 91].  This leads to a variety of symptoms that patients can 
present with making diagnosis and treatment more challenging. 
There are currently many therapeutics in use to treat SLE, however, there are no 
cures.  In addition, many of the therapies rely on immunosuppression, which can have 
negative impacts on the immune system allowing for an increased risk of infection.  The 
drugs themselves can also have negative impacts on SLE patients with prolonged use.  New 
treatments are focused on neutralization of cytokines overproduced in SLE patients, such as 
anti-IL-10, anti-TNF, and most recently anti-BAFF antibodies [124, 126, 134, 135].  In 
addition, there has been utilization of anti-CD20 antibody treatment which promotes the 
removal of B cells, including autoreactive and memory B cells, but plasma cells are 
unaffected since they do not express CD20 [124, 166].  Autoantibodies are made by plasma 
cells and since they are not being depleted by this therapy, it is not as potent and has been 
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found to be ineffective in relieving symptoms if complete CD20+ B cell depletion does not 
occur [124]. 
Interestingly, SLE treatments have never been pursued toward the removal of 
apoptotic cells and immune complexes.  Apoptotic cells and immune complexes contribute 
to activation of autoreactive B cells, autoantibody production, and tissue inflammation [61, 
64, 96, 142].  Therefore, we developed a novel approach to address this component.  The 
use of healthy dendritic cells and macrophages injected into the patient is a therapy that 
was tested in Chapter 2.  The goal of this therapy is to remove the apoptotic cell burden 
that contributes to immune complex deposition in tissues and activation of autoreactive 
cells along with clearance of the immune complexes themselves. Removal of apoptotic cells 
and immune complexes should decrease inflammation and prevent further tissue damage 
(Figure 3.1).  In the process, the reduction of autoantibodies may be possible through 
removal of plasma cell survival niches in inflamed tissues (Figure 3.1).  Finally, autoreactive 
cells should become susceptible to regulation mechanisms through reduction of the 
dysregulating antigens.  While the preliminary results did not show everything that was 
expected, optimization could allow for these outcomes.   
One of the key organs subjected to damage by immune complexes is the kidney.  
Through deposition of immune complexes in glomeruli of the kidney, inflammation occurs 
and promotes the production of cytokines [49, 111].  These cytokines induce homing of 
immune cells into the kidney to clear immune complexes and remove inflammation [49].  
However, phagocytes from SLE patients are unable to clear the immune complexes further 
exacerbating the inflammation and tissue damage through production of additional 
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cytokines [64, 96, 102].  In addition, plasma cells have been found in the inflamed kidneys of 
lupus-prone NZB/W F1 mice in inflammatory cytokine produced niches [87].  Their 
production of antibodies in the kidney can contribute to the already present problem of 
immune complexes [86, 91].  The goal with the DC/M injection treatment is that some of 
the cells will migrate to the kidney and help clear the apoptotic cells and immune 
complexes being deposited there.  Through this process, the apoptotic cells and immune 
complexes will be cleared, inflammation will be reduced in the kidneys, and the infiltrating 
immune cells will leave.  There is also the benefit of stopping the production of all the pro-
inflammatory cytokines that contribute to the survival of plasma cells in the niches.  
Ultimately, this could prevent further damage to the kidney and organ failure and 
potentially restore tissues that have been damaged by inflammation.   
Autoantibodies are a contributing factor to pathogenesis of lupus and the ability to 
prevent their production would be extremely beneficial.  We saw that production was 
reduced in mice that were initially making IgM autoantibodies.  However, in mice that made 
all isotypes of autoantibodies we did not see any change, except for an increase in IgM 
autoantibodies in one mouse receiving cell injections (Chapter 2).  This result indicates that 
it may be difficult to prevent autoantibody production.  Previous treatments with anti-CD20 
antibody, anti-BAFF antibody, and allogeneic mesenchymal stem cells have been found to 
have little to no impact on autoantibody production [123, 124, 130, 134].  This may be due 
to the reduction of surface receptors on and location of plasma cells.    On the other hand, if 
the injection of DCs and Ms could increase the production of autoantibodies of the IgM 
isotype, there could be a decrease in disease symptoms.  Reduced disease symptoms were 
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seen in MRL/lpr mice that were capable of making only IgM antibodies and in SLE patients 
that produced more IgM than IgG autoantibodies indicating a protective role [117-119, 
121].  One of the main producers of IgM that recognizes apoptotic cells are B-1 B cells [104, 
107].  The expansion of this B cell population or stimulation by BCR or TLR to produce 
increased amounts of natural IgM through DC/M injection would promote regulation of 
symptoms [104, 116].  This regulation is due to their ability to promote clearance of 
apoptotic cells in a non-inflammatory process through complement receptors and not by Fc 
receptors that promote inflammation, as would be seen by IgG autoantibodies [61, 76, 77, 
107, 109, 110].  Therefore, IgM autoantibodies would help enhance clearance of apoptotic 
cells and potentially reduce inflammation.  In addition, even if this treatment is unable to 
affect the autoantibody levels, if the apoptotic cell burden and apoptotic cell debris is 
removed, then the autoantibodies would have no antigen to bind and even though present 
in the serum would have no impacts on the patient’s health.  
Another idea of a therapeutic is the use of bone marrow chimeras, where the 
patient would undergo a nonmyeloablative transplant.  The goal of this technique is the 
same as the cell injection, but the healthy dendritic cells and macrophages would be 
produced by the bone marrow received by the patient.  This therapy would allow for 
continued production of healthy dendritic cells and macrophages throughout the remainder 
of the patient’s life, rather than potentially having to get injections throughout their life 
with the proposed injection treatment.  Currently, no effect on the production of IgG 
autoantibodies have been seen in MRL/lpr mice treated with wild-type bone marrow, which 
is similar to the DC/M injection results indicating that both treatments appear to be 
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incapable of impacting autoantibody producing plasma cells.  The kidneys have yet to be 
examined for inflammation and infiltration of immune cells.  However, absent or reduced 
inflammation and infiltration compared to control mice, would indicate that introducing 
healthy DCs and Ms into lupus-prone mice will reduce disease symptoms.  However, these 
treatments require allograft transplants requiring little to no MHC mismatch between the 
donor and recipient to reduce the chance and severity of the recipient developing graft-
versus-host disease.  This may make the treatments more of a challenge, but positive 
results would make them beneficial to pursue [127, 133].   
Based on our results and the potential benefits that could be obtained with 
improvement of the current therapy protocol, there could be increased improvements 
through the use of this therapy in combination with others.  The main goal of our therapy is 
to remove the apoptotic cells, which is the basis of the immune complexes.  However, the 
new anti-BAFF therapy can impact B cell survival, including plasma cells [89].  Therefore, if 
we used our therapy along with the anti-BAFF therapy, then we could eliminate both 
components of the immune complexes and potentially prevent the production of 
autoantibodies in the future if the apoptotic burden remained low and if all IgG isotype 
autoantibody-producing plasma cells were removed.  In addition, there may be other 
therapies that could be utilized to help improve our therapy, such as anti-IL-10.  Since IL-10 
levels are increased in lupus patients, its ability to prevent inflammation becomes 
dysregulated along with being involved in increased apoptosis and disease activity [82, 100, 
131].  By including the anti-IL-10 therapy along with either the DC/M cell injection alone 
or with the anti-BAFF therapy, we could block the additional IL-10 that is likely to be 
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produced by the injected cells on contact with apoptotic cells that would contribute to 
increased disease activity.    Ultimately, even if some goals of our therapy were not possible, 
combining it with other therapies could synergistically improve the overall benefits of all the 
therapies utilized. 
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Figure 3.1 DC/M injection to reduce apoptotic cells, inflammation, and disease 
pathogenesis.  Lupus patients would have immune complexes being deposited into tissues 
throughout their body, which would promote inflammation.  Through injection of DCs and 
Ms, the immune complexes and apoptotic cells would be cleared.  This would then lead to 
a reduction in inflammation and potentially autoantibody production through the removal 
of plasma survival niches, which have been found in the kidney [87, 91]. 
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